Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
CC transcript
Appointed director
SANGAMO THERAPEUTICS, INC (SGMO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SC 13G/A WASATCH ADVISORS LP reports a 10.2% stake in Sangamo Therapeutics, Inc.
08/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2023 FINANCIAL RESULTS"
06/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FIFTH CERTIFICATE OF AMENDMENT OF THE SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION",
"SIXTH CERTIFICATE OF AMENDMENT OF THE SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION",
"RESTATED CERTIFICATE OF INCORPORATION",
"2. SHARES SUBJECT TO THE PLAN."
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/26/2023 8-K Quarterly results
04/24/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/17/2023 ARS Form ARS - Annual Report to Security Holders:
04/17/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/05/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/17/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
03/14/2023 8-K Other Events  Interactive Data
03/10/2023 8-K Other Events  Interactive Data
03/07/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "AMENDMENT NO. 3 TO OPEN MARKET SALE AGREEMENTSM",
"Exhibit 5.1 Chadwick L. Mills"
03/02/2023 8-K Regulation FD Disclosure  Interactive Data
02/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/22/2023 8-K Quarterly results
Docs: "SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS"
02/22/2023 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
02/09/2023 SC 13G/A WASATCH ADVISORS INC reports a 7.7% stake in Sangamo Therapeutics, Inc.
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 8.6% stake in Sangamo Therapeutics Inc.
02/07/2023 SC 13G/A STATE STREET CORP reports a 6% stake in AMENDED FILING SANGAMO THERAPEUTICS INC
01/24/2023 SC 13G/A BlackRock Inc. reports a 9.4% stake in SANGAMO THERAPEUTICS INC
12/23/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/23/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AMENDMENT NO. 2 TO OPEN MARKET SALE AGREEMENT",
"Exhibit 5.1 Chadwick L. Mills"
12/19/2022 8-K Quarterly results
12/09/2022 8-K Other Events  Interactive Data
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
09/22/2022 8-K Other Events  Interactive Data
08/30/2022 8-K Other Events  Interactive Data
08/09/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy